Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald G Hall

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Diagnostic Microbiology and Infectious Disease|June 19, 2003
In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosaDavid S Burgess, Ronald G Hall, Thomas C Hardin
BMC Infectious Diseases|March 4, 2014
Therapy duration and long-term outcomes in extra-pulmonary tuberculosisTobias Pusch, Jotam G Pasipanodya, Ronald G Hall, et al.
Expert Review of Clinical Pharmacology|December 1, 2017
Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options)Kenna D Payne, Amrita Das, Michelle Ndiulor, et al.
The Annals of Pharmacotherapy|November 22, 2013
Dosing considerations for obese patients receiving cancer chemotherapeutic agentsRonald G Hall, Gary W Jean, Meredith Sigler, et al.
Antibiotics (Basel, Switzerland)|March 25, 2022
The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health FactsRonald G Hall, Travis J Cole, Chip Shaw, et al.
Journal of Intensive Care Medicine|July 13, 2010
Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mindAmy Arnold, Sara D Brouse, William D Pitcher, et al.
Pharmacy (Basel, Switzerland)|August 27, 2021
Potential Excess Intravenous Antibiotic Therapy in the Setting of Gram-Negative BacteremiaAshley R Selby, Jaffar Raza, Duong Nguyen, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourthsRonald G Hall, Mark A Swancutt, Claudia Meek, et al.
Expert Opinion on Pharmacotherapy|September 12, 2018
An evaluation of tedizolid for the treatment of MRSA infectionsRonald G Hall, Winter J Smith, William C Putnam, et al.
The Annals of Pharmacotherapy|February 10, 2011
Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Travis W Cooper, Steven E Pass, Sara D Brouse, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Diagnostic Microbiology and Infectious Disease|June 19, 2003
In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosaDavid S Burgess, Ronald G Hall, Thomas C Hardin
BMC Infectious Diseases|March 4, 2014
Therapy duration and long-term outcomes in extra-pulmonary tuberculosisTobias Pusch, Jotam G Pasipanodya, Ronald G Hall, et al.
Expert Review of Clinical Pharmacology|December 1, 2017
Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options)Kenna D Payne, Amrita Das, Michelle Ndiulor, et al.
The Annals of Pharmacotherapy|November 22, 2013
Dosing considerations for obese patients receiving cancer chemotherapeutic agentsRonald G Hall, Gary W Jean, Meredith Sigler, et al.
Antibiotics (Basel, Switzerland)|March 25, 2022
The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health FactsRonald G Hall, Travis J Cole, Chip Shaw, et al.
Journal of Intensive Care Medicine|July 13, 2010
Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mindAmy Arnold, Sara D Brouse, William D Pitcher, et al.
Pharmacy (Basel, Switzerland)|August 27, 2021
Potential Excess Intravenous Antibiotic Therapy in the Setting of Gram-Negative BacteremiaAshley R Selby, Jaffar Raza, Duong Nguyen, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourthsRonald G Hall, Mark A Swancutt, Claudia Meek, et al.
Expert Opinion on Pharmacotherapy|September 12, 2018
An evaluation of tedizolid for the treatment of MRSA infectionsRonald G Hall, Winter J Smith, William C Putnam, et al.
The Annals of Pharmacotherapy|February 10, 2011
Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Travis W Cooper, Steven E Pass, Sara D Brouse, et al.
Pageof 8